Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 16;8(1):24.
doi: 10.1186/s13643-018-0906-3.

Perioperative use of gabapentinoids for the management of postoperative acute pain: protocol of a systematic review and meta-analysis

Michael Verret  1   2 , François Lauzier  1   2   3 , Ryan Zarychanski  4 , Xavier Savard  2 , Marie-Joëlle Cossi  2 , Anne-Marie Pinard  1 , Guillaume Leblanc  1 , Alexis F Turgeon  5   6   7
Affiliations

Perioperative use of gabapentinoids for the management of postoperative acute pain: protocol of a systematic review and meta-analysis

Michael Verret et al. Syst Rev. .

Abstract

Background: Opioids are commonly used for the management of postoperative pain, but their use is limited by important adverse events, such as respiratory depression and the potential for addiction. Multimodal opioid-sparing analgesia regimens can be effectively employed to manage postoperative pain and reduce exposure to opioids. Gabapentinoids (pregabalin and gabapentin) represent an attractive class of drugs for use in multimodal regimens. The American Pain Society recommends the use of gabapentinoids during the perioperative period; however, evidence to inform such a recommendation is unclear.

Methods: We will conduct a systematic review and meta-analysis of randomized clinical trials evaluating the use of systemic gabapentinoids, in comparison to other analgesic regimens or placebo in adult patients undergoing surgery. We will search MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), the Web of Science, and ClinicalTrials.gov databases for relevant citations. Our primary outcome will be intensity of postoperative acute pain (12 h). Our secondary outcomes will be postoperative pain intensity at 6, 24, 48 h, and 72 h, cumulative dose of opioids administered within 24, 48, and 72 h following surgery, the length of stay, chronic pain, and adverse events. Two investigators will independently select trials and extract data. We will evaluate the risk of bias of included trials using the Cochrane risk of bias tools. We will represent pooled continuous data as weighted mean differences and pooled dichotomous data as risk ratios with a 95% confidence interval. We will use random effect models and assess statistical heterogeneity with the I2 index.

Discussion: Our study will provide the best level of evidence to inform the effect of gabapentinoids in the management of postoperative acute pain.

Systematic review registration: PROSPERO CRD42017067029.

Keywords: Acute pain; Analgesia; Anesthesiology; Gabapentinoids; Postoperative; Surgery.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105–S120. - PubMed
    1. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths--United States, 2000–2014. Morbidity and Mortality Weekly Report (MMWR) 2016;64:1378–1382. doi: 10.15585/mmwr.mm6450a3. - DOI - PubMed
    1. Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. Anesth Analg. 2017;125:1733–1740. doi: 10.1213/ane.0000000000002458. - DOI - PMC - PubMed
    1. Peter R Kamerman NBF, Liliana De Lima, Simon Haroutounian, et al. Gabapentin for Neuropathic Pain: World Health Organization; 2016. http://www.who.int/selection_medicines/committees/expert/21/applications...]. [Accessed 19 Dec 2017]
    1. FDA. Approved Labeling: Gabapentin 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020.... [Accessed 13 Nov 2017]

Publication types

MeSH terms

Grants and funding